Overcoming antibiotic resistance: the potential and pitfalls of drug repurposing DOI

Mohammad Abavisani,

Alireza Khoshrou,

S. Eshaghian

et al.

Journal of drug targeting, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 27

Published: Nov. 1, 2024

Since its emergence shortly after the discovery of penicillin, antibiotic resistance has escalated dramatically, posing a significant health threat and economic burden. Combating resistance, especially in Gram-negative bacteria (GNB) drug-resistant Mycobacterium tuberculosis, necessitates innovative research, substantial financial investment, global cooperation to safeguard public develop sustainable solutions. Drug repositioning, or drug repurposing, involves identifying new therapeutic applications for existing drugs, utilizing their established safety profiles pharmacological data swiftly provide effective treatments against resistant pathogens. Several including otilonium bromide, penfluridol, eltrombopag, ibuprofen, ceritinib, have demonstrated potent antibacterial activity multidrug-resistant (MDR) bacteria. These drugs can disrupt biofilms, damage bacterial membranes, inhibit growth. Furthermore, combination repurposed with conventional antibiotics reduce required dosage individual mitigate side effects, delay development making it promising strategy MDR such as Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli. Despite promise, repurposing faces challenges potential off-target toxicity, regulatory intellectual property issues, necessitating rigorous evaluations strategic This article aims explore combat examining benefits, challenges, future prospects. We address legal, economic, practical associated highlight successful examples, propose solutions enhance efficacy viability this approach combating infections.

Language: Английский

Overcoming antibiotic resistance: the potential and pitfalls of drug repurposing DOI

Mohammad Abavisani,

Alireza Khoshrou,

S. Eshaghian

et al.

Journal of drug targeting, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 27

Published: Nov. 1, 2024

Since its emergence shortly after the discovery of penicillin, antibiotic resistance has escalated dramatically, posing a significant health threat and economic burden. Combating resistance, especially in Gram-negative bacteria (GNB) drug-resistant Mycobacterium tuberculosis, necessitates innovative research, substantial financial investment, global cooperation to safeguard public develop sustainable solutions. Drug repositioning, or drug repurposing, involves identifying new therapeutic applications for existing drugs, utilizing their established safety profiles pharmacological data swiftly provide effective treatments against resistant pathogens. Several including otilonium bromide, penfluridol, eltrombopag, ibuprofen, ceritinib, have demonstrated potent antibacterial activity multidrug-resistant (MDR) bacteria. These drugs can disrupt biofilms, damage bacterial membranes, inhibit growth. Furthermore, combination repurposed with conventional antibiotics reduce required dosage individual mitigate side effects, delay development making it promising strategy MDR such as Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli. Despite promise, repurposing faces challenges potential off-target toxicity, regulatory intellectual property issues, necessitating rigorous evaluations strategic This article aims explore combat examining benefits, challenges, future prospects. We address legal, economic, practical associated highlight successful examples, propose solutions enhance efficacy viability this approach combating infections.

Language: Английский

Citations

3